Is conformational analysis a key to solve the structure--activity problem of neuroleptics?

Review

S Misztal et al. Pharmazie. 1986 Apr.

. 1986 Apr;41(4):277-81.

No abstract available

Similar articles

Stereospecificity and clinical potency of neuroleptics.
Crow TJ, Deakin JW, Johnstone EC. Crow TJ, et al. Nature. 1977 May 12;267(5607):183-4; author reply 184. doi: 10.1038/267183c0. Nature. 1977. PMID: 16073446 No abstract available.
Agents acting on central dopamine receptors.
Kumar N, Jain PC. Kumar N, et al. Prog Drug Res. 1977;21:409-65. doi: 10.1007/978-3-0348-7098-6_5. Prog Drug Res. 1977. PMID: 22892 Review. No abstract available.
Neuroleptic activity of the 5-aryltetrahydro-gamma-carboline series. Conformational requirements for interaction with central dopamine receptors.
Harbert CA, Plattner JJ, Welch WM, Weissman A, Koe BK. Harbert CA, et al. Mol Pharmacol. 1980 Jan;17(1):38-42. Mol Pharmacol. 1980. PMID: 6104285 No abstract available.
Conformational properties of butaclamol and isobutaclamol. Regularities in the structures of semirigid neuroleptics.
Froimowitz M, Matthysse S. Froimowitz M, et al. Mol Pharmacol. 1983 Sep;24(2):243-50. Mol Pharmacol. 1983. PMID: 6193405
Brain dopamine receptors.
Seeman P. Seeman P. Pharmacol Rev. 1980 Sep;32(3):229-313. Pharmacol Rev. 1980. PMID: 6117090 Review. No abstract available.